These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15605945)

  • 1. No need to tax the sick: clinical guidelines for rofecoxib as an alternative effective method to the copayment policy in the advent of increasing pharmaceutical expenditures.
    Rosen Y; Yachelevich N; Benedek P; Grotto I; Goldberg A; Morad Y; Marom H; Ohana N; Bar-Dayan Y
    Mil Med; 2004 Nov; 169(11):932-6. PubMed ID: 15605945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E; Hunsche E; Toubouti Y; Chabot I
    Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From civilian service to military service: what led policy-makers to remove nursing care from field units of the Israeli defense force (IDF) and return it later?
    Segev R
    Isr J Health Policy Res; 2019 Dec; 9(1):1. PubMed ID: 31892364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of an evidence-based managerial decision aid to assist in the provision of secondary medical services in the Israel Defense Forces (IDF)].
    Green I; Huerta M; Bar-Dayan Y; Fire G
    Harefuah; 2009 Apr; 148(4):243-7, 276. PubMed ID: 19630347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
    Weideman RA; Kelly KC; Kelley CL; Cryer B
    Am J Manag Care; 2002 Oct; 8(10):869-77. PubMed ID: 12395955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
    Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
    Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
    Dai C; Stafford RS; Alexander GC
    Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
    van der Veen WJ; van der Werf GT
    Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [OUTSOURCING OF MEDICAL SERVICES FOR SOLDIERS TO CIVILIAN HEALTH FUNDS].
    Ash N
    Harefuah; 2018 Oct; 157(10):660-663. PubMed ID: 30343546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
    Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Various contract settings and their impact on the cost of medical services.
    Magnezi R; Dankner R; Kedem R; Reuveni H
    J R Army Med Corps; 2007 Mar; 153(1):22-5. PubMed ID: 17575873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of prescription practices and of the rational use of medicines in Niger].
    Mallet HP; Njikam A; Scouflaire SM
    Sante; 2001; 11(3):185-93. PubMed ID: 11641083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
    Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
    Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of magnetic resonance imaging regulatory methods in the Israeli Air Force.
    Levy G; Goldstein L; Paz I; Atar E; Olsha S; Goldberg A; Bar Dayan Y
    Mil Med; 2007 May; 172(5):478-81. PubMed ID: 17521093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reorganization of secondary medical care in the Israeli Defense Forces Medical Corps: A cost-effect analysis.
    Yagil Y; Arnon R; Ezra V; Ashkenazi I
    Mil Med; 2006 Dec; 171(12):1229-34. PubMed ID: 17256690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J; Diggins DA; Morrill GB
    Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk.
    Thiebaud P; Patel BV; Nichol MB
    Value Health; 2006; 9(6):361-8. PubMed ID: 17076866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.